Search company, investor...
Intercell company logo



Acq - P2P | Acquired

About Intercell

Intercell AG, (formerly Iomai Corp.) has developed a method to safely and more effectively deliver vaccines through the use of a skin patch and without any injections.

Headquarters Location

Campus Vienna Biocenter 6


Missing: Intercell's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Intercell's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Intercell Patents

Intercell has filed 41 patents.

The 3 most popular patent topics include:

  • Association football forwards
  • Instruction processing
  • Job scheduling
patents chart

Application Date

Grant Date


Related Topics




Acetylcholinesterase inhibitors, Organophosphate insecticides, Bacterial toxins, Immunology, Proteins


Application Date


Grant Date



Related Topics

Acetylcholinesterase inhibitors, Organophosphate insecticides, Bacterial toxins, Immunology, Proteins



Latest Intercell News

Lear to Supply Electrification Technologies for GM's Ultium Battery Platform

Sep 14, 2022

09/14/2022 | 10:31am EDT Message : Intercell Connect Boards, Battery Disconnect Units Enhance EV Performance SOUTHFIELD, Mich., Sept. 14, 2022 /PRNewswire/ -- Lear Corporation (NYSE: LEA), a global automotive technology leader in Seating and E-Systems, announced it has been selected by General Motors Co. to supply key electrification technologies for the automaker's Ultium global electric vehicle platform. "We are honored to have been selected to provide technologies to support GM's vision for a zero-emissions future," said Ray Scott, Lear's President and Chief Executive Officer. "Lear's unique electrification engineering knowledge and molding and precision stamping capabilities, combined with our strategically located manufacturing facilities, perfectly positioned Lear to win this new business, which includes the largest award to date for our Connection Systems business." The technologies Lear will provide include: Battery Disconnect Units (BDU) - BDUs are the primary interface between the battery pack and the vehicle's electrical system. Lear's patent-holding and PACE Award-winning BDU has first-to-market thermal management innovations that enable vehicles to charge faster and drive farther. Intercell Connect Boards (ICB)- ICBs are the electrical and mechanical frames that hold together multiple individual battery cells to form an integrated battery module. Wire Harnesses – Wire harnesses provide electric voltage and distribute power safely and efficiently throughout the vehicle. Lear's decades of experience with electric vehicle architectures, precision metal stampings, and connection systems, along with the overmolding capabilities obtained through the 2021 acquisition of M&N Plastics, provide the expertise required to engineer and produce complex parts for the Ultium program. Scott continued, "This award is a reflection of our focus on, and commitment to, using Lear's full range of in-house capabilities to develop cutting-edge innovations to meet our customers' needs." About Lear Corporation Lear, a global automotive technology leader in Seating and E-Systems, enables superior in-vehicle experiences for consumers around the world. Lear's diverse team of talented employees in 38 countries is driven by a commitment to innovation, operational excellence, and sustainability. Lear is Making every drive better™ by providing the technology for safer, smarter, and more comfortable journeys. Lear, headquartered in Southfield, Michigan, serves every major automaker in the world and ranks 186 on the Fortune 500. Further information about Lear is available at or on Twitter @LearCorporation. View original content to download multimedia: SOURCE Lear Corporation

Intercell Frequently Asked Questions (FAQ)

  • What is Intercell's latest funding round?

    Intercell's latest funding round is Acq - P2P.

  • Who are the investors of Intercell?

    Investors of Intercell include Valneva, MPM Capital, Star Ventures, Apax Partners, Thuja Capital Management and 4 more.

  • Who are Intercell's competitors?

    Competitors of Intercell include Aura Biosciences, Erydel, OptiNose, Cellnovo, Carbylan Therapeutics and 12 more.

Compare Intercell to Competitors

Global Protein Products

Global Protein Products (GPP) is a zein protein coatings company. Zein protein is the storage protein in corn kernels. It has excellent film-forming and thermoplastic characteristics.


EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.

Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

MAD Nanolayers

MAD Nanolayers aims to provide a patented coating technology for delivering multiple agents sequentially and with precise control over dosage and timing. This is a platform technology with many therapeutic and non-therapeutic applications and whose disruptive feature is not available in any other coating technology today. MAD Nanolayers' primary offering will be a therapeutic coating for orthopedic implants that aims to deliver painkillers, antibiotics, and growth factors to minimize post-surgical complications and aims to eliminate subsequent re-intervention procedures, resulting in cost-savings to the hospitals and improved quality of life for patients.

Kucera Pharmaceutical Company

Kucera Pharmaceutical Company is based in Winston-Salem, NC. The company started with a drug delivery approach that combined or conjugated delivery molecules with therapeutic molecules as a platform technology, both to improve the properties of the attached therapeutic molecules (making them orally available and improving distribution) and to extend patent life.

Nano Discovery

Nano Discovery aims to provide customer-designed synthesis and development of a range of nanomaterials including nanoparticles, quantum dots, polymers, conjugated conducting polymers, nanofibers, nanotubes, nanoporous particles, colloidal particles (liposomes and vesicles), monolayer and multilayer thin films, and nanocomposite materials. Applications of the materials include biomolecular imaging, bioassay, drug delivery, cancer therapy, electronic materials, coatings and packaging for electronic devices, coatings for corrosion protection, conformable batteries, supercapcitors, and photovoltaic cells. The company also have developed or licensed some signature nanomaterial products which can be made-to-order for the company's customers.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.